vs
Side-by-side financial comparison of Insulet Corporation (PODD) and ZIONS BANCORPORATION, NATIONAL ASSOCIATION (ZION). Click either name above to swap in a different company.
ZIONS BANCORPORATION, NATIONAL ASSOCIATION is the larger business by last-quarter revenue ($891.0M vs $783.7M, roughly 1.1× Insulet Corporation). ZIONS BANCORPORATION, NATIONAL ASSOCIATION runs the higher net margin — 29.5% vs 13.0%, a 16.6% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 8.7%). ZIONS BANCORPORATION, NATIONAL ASSOCIATION produced more free cash flow last quarter ($952.0M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 9.6%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Zions Bancorporation is an American national bank headquartered in Salt Lake City, Utah. It operates as a national bank rather than as a bank holding company and does business under the following seven brands: Zions Bank, Amegy Bank of Texas, California Bank and Trust, National Bank of Arizona, Nevada State Bank, Vectra Bank Colorado, and the Commerce Bank of Washington.
PODD vs ZION — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $891.0M |
| Net Profit | $101.6M | $263.0M |
| Gross Margin | 72.6% | — |
| Operating Margin | 18.7% | — |
| Net Margin | 13.0% | 29.5% |
| Revenue YoY | 31.2% | 8.7% |
| Net Profit YoY | 0.9% | 21.8% |
| EPS (diluted) | $1.42 | $1.77 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $783.7M | $891.0M | ||
| Q3 25 | $706.3M | $861.0M | ||
| Q2 25 | $649.1M | $838.0M | ||
| Q1 25 | $569.0M | $795.0M | ||
| Q4 24 | $597.5M | $820.0M | ||
| Q3 24 | $543.9M | $792.0M | ||
| Q2 24 | $488.5M | $777.0M | ||
| Q1 24 | $441.7M | $742.0M |
| Q4 25 | $101.6M | $263.0M | ||
| Q3 25 | $87.6M | $222.0M | ||
| Q2 25 | $22.5M | $244.0M | ||
| Q1 25 | $35.4M | $170.0M | ||
| Q4 24 | $100.7M | $216.0M | ||
| Q3 24 | $77.5M | $214.0M | ||
| Q2 24 | $188.6M | $201.0M | ||
| Q1 24 | $51.5M | $153.0M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — | ||
| Q1 24 | 69.5% | — |
| Q4 25 | 18.7% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 18.7% | — | ||
| Q1 25 | 15.6% | — | ||
| Q4 24 | 18.3% | — | ||
| Q3 24 | 16.2% | — | ||
| Q2 24 | 11.2% | — | ||
| Q1 24 | 12.9% | — |
| Q4 25 | 13.0% | 29.5% | ||
| Q3 25 | 12.4% | 25.8% | ||
| Q2 25 | 3.5% | 29.1% | ||
| Q1 25 | 6.2% | 21.4% | ||
| Q4 24 | 16.9% | 26.3% | ||
| Q3 24 | 14.2% | 27.0% | ||
| Q2 24 | 38.6% | 25.9% | ||
| Q1 24 | 11.7% | 20.6% |
| Q4 25 | $1.42 | $1.77 | ||
| Q3 25 | $1.24 | $1.48 | ||
| Q2 25 | $0.32 | $1.63 | ||
| Q1 25 | $0.50 | $1.13 | ||
| Q4 24 | $1.38 | $1.34 | ||
| Q3 24 | $1.08 | $1.37 | ||
| Q2 24 | $2.59 | $1.28 | ||
| Q1 24 | $0.73 | $0.96 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $930.8M | $1.5B |
| Stockholders' EquityBook value | $1.5B | $7.2B |
| Total Assets | $3.2B | $89.0B |
| Debt / EquityLower = less leverage | 0.61× | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $930.8M | $1.5B | ||
| Q3 25 | $934.9M | $1.5B | ||
| Q2 25 | $939.0M | $970.0M | ||
| Q1 25 | $1.6B | $964.0M | ||
| Q4 24 | $1.3B | $950.0M | ||
| Q3 24 | $1.4B | $548.0M | ||
| Q2 24 | $1.4B | $546.0M | ||
| Q1 24 | $1.4B | $544.0M |
| Q4 25 | $1.5B | $7.2B | ||
| Q3 25 | $1.4B | $6.9B | ||
| Q2 25 | $1.5B | $6.6B | ||
| Q1 25 | $1.3B | $6.3B | ||
| Q4 24 | $1.2B | $6.1B | ||
| Q3 24 | $1.1B | $6.4B | ||
| Q2 24 | $998.4M | $6.0B | ||
| Q1 24 | $790.7M | $5.8B |
| Q4 25 | $3.2B | $89.0B | ||
| Q3 25 | $3.0B | $88.5B | ||
| Q2 25 | $3.5B | $88.9B | ||
| Q1 25 | $3.5B | $88.0B | ||
| Q4 24 | $3.1B | $88.8B | ||
| Q3 24 | $3.0B | $87.0B | ||
| Q2 24 | $2.9B | $87.6B | ||
| Q1 24 | $2.6B | $87.1B |
| Q4 25 | 0.61× | 0.21× | ||
| Q3 25 | 0.68× | 0.21× | ||
| Q2 25 | 0.64× | 0.15× | ||
| Q1 25 | 1.21× | 0.15× | ||
| Q4 24 | 1.07× | 0.16× | ||
| Q3 24 | 1.21× | 0.09× | ||
| Q2 24 | 1.36× | 0.09× | ||
| Q1 24 | 1.72× | 0.09× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $1.1B |
| Free Cash FlowOCF − Capex | $48.2M | $952.0M |
| FCF MarginFCF / Revenue | 6.2% | 106.8% |
| Capex IntensityCapex / Revenue | 17.2% | 13.6% |
| Cash ConversionOCF / Net Profit | 1.80× | 4.08× |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | $1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.3M | $1.1B | ||
| Q3 25 | $125.7M | $438.0M | ||
| Q2 25 | $196.5M | $-62.0M | ||
| Q1 25 | $63.8M | $179.0M | ||
| Q4 24 | $147.7M | $1.1B | ||
| Q3 24 | $98.5M | $119.0M | ||
| Q2 24 | $96.5M | $251.0M | ||
| Q1 24 | $87.6M | $261.0M |
| Q4 25 | $48.2M | $952.0M | ||
| Q3 25 | $100.1M | $413.0M | ||
| Q2 25 | $177.9M | $-93.0M | ||
| Q1 25 | $51.5M | $152.0M | ||
| Q4 24 | $94.1M | $1.1B | ||
| Q3 24 | $71.8M | $97.0M | ||
| Q2 24 | $74.0M | $234.0M | ||
| Q1 24 | $65.5M | $231.0M |
| Q4 25 | 6.2% | 106.8% | ||
| Q3 25 | 14.2% | 48.0% | ||
| Q2 25 | 27.4% | -11.1% | ||
| Q1 25 | 9.1% | 19.1% | ||
| Q4 24 | 15.7% | 128.2% | ||
| Q3 24 | 13.2% | 12.2% | ||
| Q2 24 | 15.1% | 30.1% | ||
| Q1 24 | 14.8% | 31.1% |
| Q4 25 | 17.2% | 13.6% | ||
| Q3 25 | 3.6% | 2.9% | ||
| Q2 25 | 2.9% | 3.7% | ||
| Q1 25 | 2.2% | 3.4% | ||
| Q4 24 | 9.0% | 11.8% | ||
| Q3 24 | 4.9% | 2.8% | ||
| Q2 24 | 4.6% | 2.2% | ||
| Q1 24 | 5.0% | 4.0% |
| Q4 25 | 1.80× | 4.08× | ||
| Q3 25 | 1.43× | 1.97× | ||
| Q2 25 | 8.73× | -0.25× | ||
| Q1 25 | 1.80× | 1.05× | ||
| Q4 24 | 1.47× | 5.31× | ||
| Q3 24 | 1.27× | 0.56× | ||
| Q2 24 | 0.51× | 1.25× | ||
| Q1 24 | 1.70× | 1.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
ZION
Segment breakdown not available.
